Markets:

Overview

News

Currencies

International

Treasuries

Protalix BioTherapeutics, Inc. (DE) Common Stock (NY:PLX)

2.715 +0.005 (+0.18%)

Delayed Quote Updated: 3:35 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Protalix BioTherapeutics, Inc. (DE) Common Stock

< Previous 1 2 3 4 5 Next >

Earnings Scheduled For November 14, 2022 ↗

November 14, 2022

Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.

Via Benzinga

Earnings Scheduled For May 16, 2022 ↗

May 16, 2022

Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.

Via Benzinga

Protalix PRX-102: Likely Approval Could Be A Game Changer ↗

May 02, 2022

Protalix's PRX-102 drug stands a good chance of being accepted against Fabry disease, with three P3 trials delivering good results.

Via Talk Markets

Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions

September 21, 2022

As many investors are aware, options market data can provide some critical insight into future price movements of underlying common stock. It’s often possible to tell how the broader market perceives a...

Via TheNewswire.com

Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions

September 21, 2022

By Mark Gilman, Benzinga

Via News Direct

Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions ↗

September 20, 2022

Via Benzinga

10 Most-Searched Tickers On Benzinga Pro In April: Musk Mania, Apple Drops, Several Newcomers Move Up ↗

May 02, 2022

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. Here is a look at the...

Via Benzinga

Why Protalix Is Back On The Radar? ↗

April 19, 2022

After encountering bureaucratic hurdles, Protalix's PRX-102 has come through the BALANCE study with flying colors and is ready to reapply for its BLA.

Via Talk Markets

Protalix Shares Surge After Encouraging Topline Data From Another Fabry Disease Trial ↗

April 04, 2022

Via Benzinga

Earnings Scheduled For August 15, 2022 ↗

August 15, 2022

Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter.

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More ↗

April 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

68 Biggest Movers From Yesterday ↗

April 05, 2022

Gainers GBS Inc. (NASDAQ: GBS) jumped 68% to settle at $1.31 on Monday. Zacks Small-Cap Research issued a note on GBS with an $8 valuation. Aterian, Inc. (NASDAQ: ATER) shares...

Via Benzinga

Why Protalix BioTherapeutics Stock Is Soaring ↗

April 04, 2022

Protalix BioTherapeutics Inc (AMEX:PLX) shares are surging Monday after the company said its Phase 3 trial for the treatment of Fabry disease met its primary endpoint. Fabry disease is an inherited...

Via Benzinga

Protalix BioTherapeutics's Return On Capital Employed Insights ↗

April 01, 2022

Benzinga Pro data, Protalix BioTherapeutics (AMEX:PLX) reported Q4 sales of $8.55 million. Earnings fell to a loss of $6.67 million, resulting in a 58.78% decrease from last quarter.

Via Benzinga

Recap: Protalix BioTherapeutics Q4 Earnings ↗

March 31, 2022

Protalix BioTherapeutics (AMEX:PLX) reported its Q4 earnings results on Thursday, March 31, 2022 at 06:50 AM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Outlook For Protalix BioTherapeutics ↗

March 30, 2022

Protalix BioTherapeutics (AMEX:PLX) is set to give its latest quarterly earnings report on Thursday, 2022-03-31. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Protalix Bio, Chiesi Release Final Results From Late-Stage PRX-102 Trial In Fabry Disease ↗

March 18, 2022

Protalix BioTherapeutics Inc (NYSE: PLX) and Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A, have

Via Benzinga

The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill ↗

March 18, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Earnings Scheduled For March 31, 2022 ↗

March 31, 2022

Companies Reporting Before The Bell • Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth quarter.

Via Benzinga

Protalix BioTherapeutics: Management Sounds Confident Despite CRL ↗

December 30, 2021

A spate of bad bureacratic luck - including the FDA letter explaining that Covid kept them from doing an inspection - has put PLX's Fabry disease drug in an uncompetitive position, but we reached out...

Via Talk Markets

50 Biggest Movers From Friday ↗

February 07, 2022

Also check out this: Executives Sell Over $45M Of 5 Stocks Losers Ra Medical Systems, Inc. (NYSE: RMED) shares dipped 48.8% to close at $0.3599 on Friday after the...

Via Benzinga

Protalix Stock Is Trading Higher On Meeting Request To FDA For Fabry Disease Candidate Application ↗

August 02, 2021

Protalix BioTherapeutics Inc (NYSE: PLX) has submitted a Type A Meeting request to the FDA regarding PRX-102 Complete Response Letter it received in April. The...

Via Benzinga

PLX Upcoming Volatility Creates Opportunity ↗

July 27, 2021

PLX was up on FDA notice last year on a CRL postponement that its PDUFA review of PRX-102. In the meantime, phase III trials continue to provide more positive results. It is a stock worth watching.

Via Talk Markets

Earnings Scheduled For November 15, 2021 ↗

November 15, 2021

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its third quarter. • Tyson Foods (NYSE:TSN) is estimated to...

Via Benzinga

The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More ↗

November 14, 2021

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at...

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

August 17, 2021

Tuesday morning, 282 companies set new 52-week lows. Key Facts: Alibaba Group Holding (NYSE:BABA) was the biggest company by market cap to set a new 52-week low....

Via Benzinga

Earnings Scheduled For August 16, 2021 ↗

August 16, 2021

Companies Reporting Before The Bell • Entera Bio (NASDAQ:ENTX) is likely to report earnings for its second quarter. • Data Storage (NASDAQ:DTST) is expected to...

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

August 13, 2021

Friday morning, 94 companies reached new 52-week lows. Significant Points: Wix.com (NASDAQ:WIX) is the largest company in terms of market cap to set a new 52-week...

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

July 19, 2021

Stocks That Hit 52-Week Lows On Monday Monday morning, 285 companies reached new 52-week lows. Noteworthy Points: The largest company by market cap to set a new 52-week...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

July 07, 2021

Before 10 a.m. ET on Wednesday, 49 companies set new 52-week lows. Noteworthy Highlights: The largest company in terms of market cap to set a new 52-week low was China...

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Protalix BioTherapeutics, Inc. (DE) Common Stock (NY:PLX)

All News about Protalix BioTherapeutics, Inc. (DE) Common Stock

Starting at /week.